ロモソズマブ (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "ロモソズマブ" in Japanese language version.

refsWebsite

Global rank Japanese rank

8nih.gov

4^th place

24^th place

5doi.org

2^nd place

6^th place

2fda.gov

447^th place

1,043^rd place

2europeanpharmaceuticalreview.com

low place

1canada.ca

1,712^th place

7,476^th place

1hres.ca

low place

1web.archive.org

1^st place

1ama-assn.org

3,257^th place

6,629^th place

1nikkeibp.co.jp

1,415^th place

95^th place

1kegg.jp

low place

2,161^st place

1handle.net

102^nd place

78^th place

1standard.co.uk

238^th place

1,939^th place

ama-assn.org

“Statement On A Nonproprietary Name Adopted By The USAN Council: Romosozumab”. American Medical Association. 2012年9月29日時点のオリジナルよりアーカイブ。2024年3月17日閲覧。

canada.ca

health-products.canada.ca

“Evenity Product information”. Health Canada (25 April 2012). 29 May 2022閲覧。

doi.org

“Antibodies to watch in 2020”. mAbs 12 (1): 1703531. (2020). doi:10.1080/19420862.2019.1703531. PMC 6973335. PMID 31847708.
“Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis” (英語). The New England Journal of Medicine 377 (15): 1417–1427. (October 2017). doi:10.1056/nejmoa1708322. hdl:2158/1094968. PMID 28892457.
“Romosozumab Treatment in Postmenopausal Women with Osteoporosis” (英語). The New England Journal of Medicine 375 (16): 1532–1543. (October 2016). doi:10.1056/nejmoa1607948. PMID 27641143.
Stokar, Joshua; Szalat, Auryan (14 March 2024). “Cardiovascular Safety of Romosozumab vs. PTH Analogs for Osteoporosis Treatment: a Propensity Score Matched Cohort Study”. The Journal of Clinical Endocrinology & Metabolism. doi:10.1210/clinem/dgae173.
“Antibodies to watch in 2020”. mAbs 12 (1): 1703531. (2020). doi:10.1080/19420862.2019.1703531. PMC 6973335. PMID 31847708.

europeanpharmaceuticalreview.com

fda.gov

"FDA approves new treatment for osteoporosis in postmenopausal women at high risk of fracture". U.S. Food and Drug Administration (FDA) (Press release). 9 April 2019. 2019年4月12日閲覧。
“Drug Trials Snapshot: Evenity”. U.S. Food and Drug Administration (FDA) (26 May 2021). 2024年3月17日閲覧。

handle.net

hdl.handle.net

“Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis” (英語). The New England Journal of Medicine 377 (15): 1417–1427. (October 2017). doi:10.1056/nejmoa1708322. hdl:2158/1094968. PMID 28892457.

hres.ca

hpr-rps.hres.ca

“Summary Basis of Decision (SBD) for Evenity”. Health Canada (23 October 2014). 29 May 2022閲覧。

kegg.jp

“医療用医薬品 : イベニティ (イベニティ皮下注105mgシリンジ)”. www.kegg.jp. 2024年3月17日閲覧。

nih.gov

pubmed.ncbi.nlm.nih.gov

“Antibodies to watch in 2020”. mAbs 12 (1): 1703531. (2020). doi:10.1080/19420862.2019.1703531. PMC 6973335. PMID 31847708.
“Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis” (英語). The New England Journal of Medicine 377 (15): 1417–1427. (October 2017). doi:10.1056/nejmoa1708322. hdl:2158/1094968. PMID 28892457.
“Romosozumab Treatment in Postmenopausal Women with Osteoporosis” (英語). The New England Journal of Medicine 375 (16): 1532–1543. (October 2016). doi:10.1056/nejmoa1607948. PMID 27641143.
“Antibodies to watch in 2020”. mAbs 12 (1): 1703531. (2020). doi:10.1080/19420862.2019.1703531. PMC 6973335. PMID 31847708.

ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov

nikkeibp.co.jp

medical.nikkeibp.co.jp

“イベニティ皮下注105mgシリンジの基本情報”. 日経メディカル. 2024年3月17日閲覧。

standard.co.uk

“NHS medics call for osteoporosis drug to be recommended in England and Wales”. Evening Standard (2 January 2022). 2024年3月17日閲覧。

web.archive.org

“Statement On A Nonproprietary Name Adopted By The USAN Council: Romosozumab”. American Medical Association. 2012年9月29日時点のオリジナルよりアーカイブ。2024年3月17日閲覧。